
## Fellype Carvalho Barreto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5456176/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation. European Journal of Pediatrics, 2022, 181, 715-723.	2.7	4
2	Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, 44, 249-267.	0.9	6
3	Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN). Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022. 44. 268-280.	0.9	3
4	In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients. Clinics, 2021, 76, e1821.	1.5	5
5	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. Toxicology and Applied Pharmacology, 2021, 414, 115412.	2.8	18
6	The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry disease. Molecular Genetics & Genomic Medicine, 2021, 9, e1666.	1.2	26
7	MO017THERAPEUTICAL POTENTIAL OF ENZYME REPLACEMENT: NEW INSIGHTS AND PERSPECTIVES IN HUMAN ENDOTHELIAL CELLS TREATED WITH CHLOROQUINE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
8	Renal Manifestations of Fabry Disease: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812098562.	1.1	18
9	Treatment of Osteoporosis in Chronic Kidney Disease. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 654-659.	0.9	0
10	Aluminum Intoxication in Chronic Kidney Disease. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 660-664.	0.9	8
11	Hypovitaminosis D in chronic kidney disease. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 639-644.	0.9	1
12	Update of Brazilian Guidelines for Treatment and Assessment of Chronic Kidney Disease – Mineral and Bone Disorders. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, 43, 613-614.	0.9	1
13	How do Uremic Toxins Affect the Endothelium?. Toxins, 2020, 12, 412.	3.4	35
14	Indoxyl Sulfate Contributes to Uremic Sarcopenia by Inducing Apoptosis in Myoblasts. Archives of Medical Research, 2020, 51, 21-29.	3.3	16
15	Letter to the Editor: "Nephrocalcinosis and Nephrolithiasis in X-Linked Hypophosphatemic Rickets: Diagnostic Imaging and Risk Factors― Journal of the Endocrine Society, 2020, 4, bvaa013.	0.2	0
16	Rare inherited kidney diseases: an evolving field in Nephrology. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 219-230.	0.9	3
17	Vitamin D and chronic kidney disease: an uneasy relationship. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 386-387.	0.9	0
18	The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 336-344.	0.9	5

Fellype Carvalho Barreto

#	Article	IF	CITATIONS
19	Strategies for Phosphate Control in Patients With CKD. Kidney International Reports, 2019, 4, 1043-1056.	0.8	74
20	Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets. Toxins, 2019, 11, 267.	3.4	19
21	Sevelamer reduces endothelial inflammatory response to advanced glycation end products. CKJ: Clinical Kidney Journal, 2018, 11, 89-98.	2.9	21
22	A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women. Nephron, 2018, 138, 147-156.	1.8	12
23	The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis. PLoS ONE, 2018, 13, e0197994.	2.5	3
24	Macrothrombocytopenia, renal dysfunction and nephrotic syndrome in a young male patient: a case report of MYH9-related disease. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2018, 40, 198-200.	0.9	5
25	Enzyme replacement therapy for Anderson-Fabry disease. The Cochrane Library, 2017, 2017, CD006663.	2.8	71
26	The complexity of chronic kidney disease–mineral and bone disorder across stages of chronic kidneyÂdisease. Kidney International, 2017, 91, 1436-1446.	5.2	117
27	Comment on Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. Toxins 2016, 8, 358. Toxins, 2017, 9, 142.	3.4	8
28	Uremia Retention Molecules and Clinical Outcomes. Contributions To Nephrology, 2017, 191, 18-31.	1.1	14
29	The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. PLoS ONE, 2017, 12, e0174811.	2.5	29
30	Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE, 2017, 12, e0173358.	2.5	71
31	SP332SEVELAMER CARBONATE REDUCES INFLAMMATION IN HUMAN ENDOTHELIAL CELLS EXPOSED TO ADVANCED GLYCATION END PRODUCTS (AGES). Nephrology Dialysis Transplantation, 2016, 31, i201-i201.	0.7	0
32	Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening. Nephron, 2016, 134, 221-230.	1.8	26
33	The pitfall of treating low bone turnover: Effects on cortical porosity. Bone, 2016, 91, 75-80.	2.9	20
34	Uremic Toxicity-Induced Eryptosis and Monocyte Modulation: The Erythrophagocytosis as a Novel Pathway to Renal Anemia. Blood Purification, 2016, 41, 317-323.	1.8	31
35	Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney International, 2015, 87, 1039-1045.	5.2	59
36	SP424ERYPTOSIS INDUCED BY INDOXYL SULFATE IS RELATED TO OXIDATIVE STRESS. Nephrology Dialysis Transplantation, 2015, 30, iii518-iii518.	0.7	0

#	Article	IF	CITATIONS
37	Peritoneal Delivery of Sodium Pyrophosphate Blocks the Progression of Pre-existing Vascular Calcification in Uremic Apolipoprotein-E Knockout Mice. Calcified Tissue International, 2015, 97, 179-192.	3.1	14
38	Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease. Journal of Bone and Mineral Metabolism, 2014, 32, 636-644.	2.7	4
39	Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney International, 2013, 84, 491-500.	5.2	50
40	Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovascular Research, 2012, 96, 130-139.	3.8	79
41	Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease. PLoS ONE, 2012, 7, e44201.	2.5	29
42	Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opinion on Pharmacotherapy, 2011, 12, 2627-2640.	1.8	27
43	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2374-2383.	4.5	119
44	High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis, 2011, 215, 116-124.	0.8	23
45	Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrology Dialysis Transplantation, 2011, 26, 3349-3357.	0.7	58
46	Estimated Glomerular Filtration Rate Is a Poor Predictor of Concentration for a Broad Range of Uremic Toxins. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1266-1273.	4.5	79
47	Prognostic Implication of Plasma Osteopontin Levels in Patients with Chronic Kidney Disease. Nephron Clinical Practice, 2011, 117, 363-372.	2.3	34
48	Inhibitors of vascular calcification as potential therapeutic targets. Journal of Nephrology, 2011, 24, 416-427.	2.0	14
49	The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 568-575.	4.5	251
50	The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2010, 25, 2596-2602.	0.7	46
51	Vascular calcification is not an independent predictor of mortality in pre-dialysis adult patients. Nephrology Dialysis Transplantation, 2010, 25, 2804-2805.	0.7	3
52	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 1183-1191.	0.7	371
53	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney International, 2010, 77, 550-556.	5.2	242
54	Uraemic toxins for consideration by the cardiologist—Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis, 2010, 211, 381-383.	0.8	18

#	Article	IF	CITATIONS
55	Fibroblast Growth Factor 23 in Hemodialysis Patients: Effects of Phosphate Binder, Calcitriol and Calcium Concentration in the Dialysate. Nephron Clinical Practice, 2010, 117, c74-c82.	2.3	59
56	Serum Ferritin Level Remains a Reliable Marker of Bone Marrow Iron Stores Evaluated by Histomorphometry in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 105-109.	4.5	46
57	Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1128-1135.	4.5	133
58	<i>Progress in Uremic Toxin Research</i> : Effects of Uremic Toxins on Vascular and Bone Remodeling. Seminars in Dialysis, 2009, 22, 433-437.	1.3	18
59	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1551-1558.	4.5	740
60	Variant of Adynamic Bone Disease in Hemodialysis Patients: Fact or Fiction?. American Journal of Kidney Diseases, 2006, 48, 430-436.	1.9	20
61	Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors. Kidney International, 2005, 67, 1576-1582.	5.2	135
62	The renal osteodystrophy pattern in Brazil and Uruguay: An overview. Kidney International, 2003, 63, S54-S56.	5.2	45